Zimmer Biomet (ZBH) Q2 FY26 earnings call

Zimmer Biomet delivered strong second-quarter results, exceeding expectations with robust organic growth, particularly in the U.S. and key segments like Hips and Technology. This performance, coupled with better-than-expected progress on its U.S. sales force transformation and new product momentum, led the company to raise its full-year revenue and adjusted EPS guidance. Management remains focused on operational excellence and innovation, while navigating pricing pressures and international headwinds, with a clear strategy for long-term growth and market share gains.